Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Lymphoma. 2014 Oct;55(10):2262-70. doi: 10.3109/10428194.2013.876634. Epub 2014 Apr 17.

Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.

Author information

1
Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center , Chicago, IL , USA.

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.

KEYWORDS:

Lymphoma and Hodgkin disease; immunotherapy; marrow and stem cell transplant clinical results; pharmacotherapeutics

PMID:
24512319
DOI:
10.3109/10428194.2013.876634
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center